Literature DB >> 8260705

Transduction of human melanoma cell lines with the human interleukin-7 gene using retroviral-mediated gene transfer: comparison of immunologic properties with interleukin-2.

A R Miller1, W H McBride, S M Dubinett, G J Dougherty, J D Thacker, H Shau, D B Kohn, R C Moen, M J Walker, R Chiu.   

Abstract

Two human melanoma cell lines were transduced with the human interleukin (IL)-7 and IL-2 genes using retroviral-mediated gene transfer. Stable, high-level cytokine expression was achieved. The in vitro growth of transduced tumors was unaltered. Neither of the IL-2-transduced melanoma cell lines grew in athymic mice, whereas one IL-7-transduced melanoma line showed retarded in vivo growth. This is consistent with animal studies suggesting a predominantly T-cell response to IL-7-transduced tumors and a more nonspecific response to IL-2-transduced tumors. Both IL-7- and IL-2-transduced melanoma cell lines could induce cytotoxic lymphocytes in mixed lymphocyte-tumor cultures. The expression of putative melanoma antigens (MAGE)-1 and MAGE-3 was unaltered by cytokine transduction. In one cell line, IL-7 transduction resulted in a marked inhibition of the immunosuppressive peptide transforming growth factor (TGF)beta 1. The results allow a comparison of immunobiologic properties of IL-7- and IL-2-transduced human melanoma cell lines in consideration of their use in genetically engineered tumor vaccines. IL-7 transduction results in stable cytokine expression and phenotypic alterations that appear to be favorable for enhanced immunogenicity and it deserves clinical testing.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8260705

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  IL-7 inhibits fibroblast TGF-beta production and signaling in pulmonary fibrosis.

Authors:  Min Huang; Sherven Sharma; Li X Zhu; Michael P Keane; Jie Luo; Ling Zhang; Marie D Burdick; Ying Q Lin; Mariam Dohadwala; Brian Gardner; Raj K Batra; Robert M Strieter; Steven M Dubinett
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

2.  Interleukin-7 gene-modified dendritic cells reduce pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma.

Authors:  Sherven Sharma; Raj K Batra; Seok Chul Yang; Sven Hillinger; Li Zhu; Kimberly Atianzar; Robert M Strieter; Karen Riedl; Min Huang; Steven M Dubinett
Journal:  Hum Gene Ther       Date:  2003-11-01       Impact factor: 5.695

Review 3.  Cytokine-mediated gene therapy for cancer.

Authors:  A R Miller; W H McBride; K Hunt; J S Economou
Journal:  Ann Surg Oncol       Date:  1994-09       Impact factor: 5.344

4.  Local and systemic response of mice to interferon-alpha 1-transfected Friend leukemia cells.

Authors:  L Gabriele; T Kaido; D Woodrow; J Moss; M Ferrantini; E Proletti; L Santodonato; C Rozera; C Maury; F Belardelli
Journal:  Am J Pathol       Date:  1995-08       Impact factor: 4.307

5.  Interleukin (IL)-7 Signaling in the Tumor Microenvironment.

Authors:  Iwona Bednarz-Misa; Mariusz A Bromke; Małgorzata Krzystek-Korpacka
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 6.  Genetically engineered mesenchymal stem cells: targeted delivery of immunomodulatory agents for tumor eradication.

Authors:  Meysam Mosallaei; Miganoosh Simonian; Naeim Ehtesham; Mohammad Reza Karimzadeh; Nasim Vatandoost; Babak Negahdari; Rasoul Salehi
Journal:  Cancer Gene Ther       Date:  2020-05-18       Impact factor: 5.987

7.  Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study.

Authors:  P Möller; Y Sun; T Dorbic; S Alijagic; A Makki; K Jurgovsky; M Schroff; B M Henz; B Wittig; D Schadendorf
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

8.  Chemo-immunotherapy with oxaliplatin and interleukin-7 inhibits colon cancer metastasis in mice.

Authors:  Hong-Feng Gou; Juan Huang; Hua-Shan Shi; Xin-Chuan Chen; Yong-Sheng Wang
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.